EU pumps EUR 2.9 million into cancer diagnostics project

The European Commission has awarded a grant of EUR 2.9 million to the COBRED project.

Funded under the Sixth Framework Programme (FP6), the COBRED project will aim to find new biomarkers for two of the most common cancers: colon cancer and breast cancer.

According to Dr Laszlo Takacs, CSO of BioSystems International, and COBRED coordinator, "This unprecedented project has the power to discover new cancer diagnostics. I am happy to see the enthusiasm of participating clinicians at the cancer centres, and of scientists at the academic and industrial laboratories."

The project will seek to develop the novel diagnostics for patient follow-up (monitoring markers) by exploiting the capacity of three state-of-the-art high-throughput technologies in an integrated systems biology approach.

After three years, COBRED hopes to deliver a set of biomarker/diagnostic candidates verified in preclinical studies, ready for large scale clinical validation and further development for commercialisation.

Furthermore, COBRED will seek to demonstrate the potential of exploring data from different high-throughput technologies and clinical profiles with advanced data mining technologies.

COBRED will also examine biomarkers for follow-up diagnostics, as novel diagnostic candidates may have the potential to aid early cancer detection via population screening. Additionally, the data gathered as part of the study may highlight poorly understood cancer mechanisms.

As breast cancer is the most common cancer in European women, and colorectal cancer is the third most common cancer type worldwide, diagnostics based on biomarkers have the potential to significantly improve current cancer disease management and diagnosis, providing higher accuracy at a lower cost.

The project consortium hopes this will lead to direct benefits for patients and society as a whole.

In addition to BioSystems International, the consortium comprises two other biotechnology firms, two large comprehensive cancer centres, three universities and a consultancy firm.

The project website will be up and running soon at the following address:
http://www.cobred.eu

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

AI Tool Helps Predict Who will Benefit f…

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who...

Research Shows AI Technology Improves Pa…

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five years of assessment. That's partly because Parkinson's sibling movement disorders...

AI in Healthcare: How do We Get from Hyp…

The Highland Marketing advisory board met to consider the government's enthusiasm for AI. To date, healthcare has mostly experimented with decision support tools, and their impact on the NHS and...

New AI Tool Accelerates Disease Treatmen…

University of Virginia School of Medicine scientists have created a computational tool to accelerate the development of new disease treatments. The tool goes beyond current artificial intelligence (AI) approaches by...

Who's to Blame When AI Makes a Medi…

Assistive artificial intelligence technologies hold significant promise for transforming health care by aiding physicians in diagnosing, managing, and treating patients. However, the current trend of assistive AI implementation could actually...

First Therapy Chatbot Trial Shows AI can…

Dartmouth researchers conducted the first clinical trial of a therapy chatbot powered by generative AI and found that the software resulted in significant improvements in participants' symptoms, according to results...

DMEA sparks: The Future of Digital Healt…

8 - 10 April 2025, Berlin, Germany. Digitalization is considered one of the key strategies for addressing the shortage of skilled workers - but the digital health sector also needs qualified...

DeepSeek: The "Watson" to Doct…

DeepSeek is an artificial intelligence (AI) platform built on deep learning and natural language processing (NLP) technologies. Its core products include the DeepSeek-R1 and DeepSeek-V3 models. Leveraging an efficient Mixture...

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...